-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The incidence and prevalence of non-alcoholic fatty liver disease (NAFLD) are rising rapidly worldwide.
The global prevalence of NAFLD for non-alcoholic fatty liver is about 25%, ranging from 13% in Africa to 42% in Southeast Asia.
According to research and analysis, it is estimated that from 2016 to 2030, the prevalence of NAFLD in China, France, Germany, Italy, Japan, Spain, the United Kingdom and the United States will increase by as much as 56%.
NAFLD is driven by metabolic syndrome and is associated with obesity, insulin resistance, and hyperlipidemia.
After the New England Journal of Medicine ( NEJM ) first announced the efficacy of semaglutide in the treatment of obese patients , four major journals , including the Lancet , the Journal of the American Medical Association, and the British Medical Journal, successively Good news came.
So people can't help but wonder whether semaglutide is also effective in treating NAFLD , which affects a quarter of the world's population ? To this end, the NN9931-4196 collaboration group jointly launched by the United Kingdom, the United States, France, Germany and other countries has carried out related research, and the results have been published again in the latest NEJM magazine.
So people can't help but wonder whether semaglutide is also effective in treating NAFLD , which affects a quarter of the world's population ? To this end, the NN9931-4196 collaboration group jointly launched by the United Kingdom, the United States, France, Germany and other countries has carried out related research, and the results have been published again in the latest NEJM magazine.
In fact, semaglutide has been previously approved for use in semaglutide.
Patients were randomly assigned to subcutaneous injection of 0.
Patients were randomly assigned to subcutaneous injection of 0.
Results A total of 320 patients were enrolled , and they were randomly assigned to receive semaglutide at doses of 0.
At the same time, 43% of patients in the 0.
At the same time, 43% of patients in the 0.
In summary, this phase 2 trial involving this NASH patient shows that the use of semaglutide treatment can benefit more NASH patients .
references:
references:Newsome PN, et al.
Leave a message here
